Mammary Cell News 11.21 June 6, 2019 | |
| |
TOP STORYHigh-Throughput Single-Cell ChIP-Seq Identifies Heterogeneity of Chromatin States in Breast Cancer Using patient-derived xenograft models of acquired resistance to chemotherapy and targeted therapy in breast cancer, researchers found that a subset of cells within untreated drug-sensitive tumors shared a common chromatin signature with resistant cells, undetectable using bulk approaches. [Nat Genet] Abstract | Press Release | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Oncogenic LncRNA Downregulates Cancer Cell Antigen Presentation and Intrinsic Tumor Suppression Scientists report that tissue-specific expression of the human long noncoding RNA (lncRNA) LINK-A in mouse mammary glands initiated metastatic mammary gland tumors, which phenotypically resembled human triple-negative breast cancer. [Nat Immunol] Abstract In various breast cancer and primary cell types the expression of the manganese superoxide dismutase (MnSOD) acetylation mimic mutant was accompanied by a change of MnSOD’s stoichiometry from a known homotetramer complex to a monomeric form. [Nat Commun] Full Article | Press Release Investigators identified Sfrp3 as a mediator of stromal-epithelial communication that was required for normal mouse mammary gland development. Loss of Sfrp3 in mice led to an increase of ductal invasion and branching mirroring an early pregnancy state. [Nat Commun] Full Article An Intelligent DNA Nanorobot with In Vitro Enhanced Protein Lysosomal Degradation of HER2 The authors report a DNA framework-based intelligent DNA nanorobot for selective lysosomal degradation of tumor-specific proteins on cancer cells. This DNA nanorobot targeted HER2-positive breast cancer cells and specifically induced the lysosomal degradation of the membrane protein HER2. [Nano Lett] Full Article | Editorial | Graphical Abstract Hypoxia-Induced Switch in SNAT2/SLC38A2 Regulation Generates Endocrine Resistance in Breast Cancer Researchers showed that the glutamine transporter, SNAT2, was the amino acid transporter most frequently induced by hypoxia in breast cancer, and was regulated by hypoxia both in vitro and in vivo in xenografts. [Proc Natl Acad Sci USA] Full Article LncRNA SNHG5 Promotes Breast Cancer Proliferation by Sponging the miR-154-5p/PCNA Axis Scientists demonstrated that small nucleolar RNA host gene 5 (SNHG5) promoted breast cancer cell proliferation both in vitro and in vivo and depletion of SNHG5 significantly led to cell cycle arrest at the G1 phase. [Mol Ther Nucleic Acids] Abstract | Full Article | Graphical Abtract Loss of PICH Promotes Chromosome Instability and Cell Death in Triple-Negative Breast Cancer Investigators report that the growth of triple-negative breast cancer (TNBC) cells was exceptionally dependent on PICH, a DNA-dependent ATPase. PICH depletion selectively impaired the proliferation of TNBC cells, but not that of luminal breast cancer cells, in vitro and in vivo. [Cell Death Dis] Full Article Changes in the CSC phenotype, in the epithelial-mesenchymal transition program, and in potential to migrate were performed to determine the possible role of wound fluids on the migration of breast cancer cells. [Sci Rep] Full Article Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News. | |
| |
REVIEWSp63 at the Crossroads between Stemness and Metastasis in Breast Cancer Investigators provide a broad picture on the physiological role of p63 in maintaining the basal epithelial identity, as well as its involvement in breast cancer progression, emphasizing its relevance in tumor cell invasion and stemness. [Int J Mol Sci] Full Article Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
INDUSTRY NEWSAngiochem Receives Loan from Quebec Government to Perform Phase III Trial Angiochem, Inc. announced that it has been granted a $4 million loan from the Quebec Government through its BioMed Propulsion program. The funds will help Angiochem conduct its Phase III clinical trial for ANG1005. [Angiochem, Inc. (GlobeNewswire, Inc.)] Press Release Oncology Venture A/S announced that the FDA has given its initial response to the company’s IND application and proposed pivotal Phase III study of LiPlaCis® in the US. The FDA has requested some additional testing of the LiPlaCis related to the product characterization. [Oncology Venture A/S] Press Release | |
| |
POLICY NEWSPowerful US Senator Calls for Vetting NIH Grantees at Hearing on Foreign Influences Research typically enjoys bipartisan support in the US Congress. But when it comes to the increasingly contentious topic of academic espionage by foreign governments, politics is never far from the surface. At a hearing of the Senate Committee on Finance, Chairman Chuck Grassley urged federal agencies to do more to thwart “real, aggressive, and ongoing” attempts by foreign entities to steal the fruits of US-funded research. [ScienceInsider] Editorial Hungarians Protest against Proposed Government Takeover of Science Thousands of scientists and their supporters marched through the streets of Budapest on 2 June to protest against a proposed law that would give the Hungarian government direct control of the country’s top research institutes. [Nature News] Editorial
| |
EVENTSNEW Keystone Symposia: Adaptive ROS Signaling in Physiology and Disease Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Canada Research Chair – Precision and Molecular Oncology (University of Calgary) NEW PhD Studentship – Molecular Mechanisms of Breast and Colorectal Cancers (Dalhousie University) NEW Senior Global Medical Director – Breast Cancer (F.Hoffmann-La Roche) Postdoctoral Fellow or Research Scientist – Cancer Biology (Icahn School of Medicine at Mount Sinai) Postdoctoral Associate – Immune Responses (The Jackson Laboratory) Postdoctoral Fellows – Bioinformatics (IRCCS European Institute of Oncology) Postdoctoral Fellowship – PcG-Mediated Mechanisms in Breast Cancer (University of Miami) Postdoctoral Fellowship – Tumor Suppressor CSMD1 (Lund University) Postdoctoral Associate – Cancer Immunology (The Jackson Laboratory) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|